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doi:10.1016/j.jfma.2011.09.006Background/Purpose: It has been shown that the abnormality in immune cells in chronic
fatigue syndrome (CFS) patients is closely associated with the participation of TGF-b. In order
to study the relationship between TGF-b1 and CFS, we investigated the mRNA levels of TGF-b1
in peripheral blood mononuclear cells (PBMCs) in patients with CFS.
Methods: Fluorescent quantitative real time reverse-transcription polymerase chain reaction
(FQ-RT-PCR) was performed to test TGF-b1 mRNA expression in PBMCs in 63 cases of CFS, 50
cases of disease controls, and 50 cases of healthy controls.
Results: The mean value of TGF-b1 mRNA expression in CFS patients was DDCtZ 1.17 0.58,
which was significantly higher than the disease controls (DDCtZ 0.07  1.08, dfZ 111,
p < 0.01) and the healthy controls (DDCtZ 0.00 1.63, dfZ 111, p < 0.01). No significant
difference was detected between disease and healthy controls (p > 0.05).
Conclusion: The expression of TGF-b1 in PBMCs is significantly elevated in patients with CFS. It
might be correlated to the pathogenesis of the disease.
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ight ª 2011, Elsevier Taiwan LLCChronic fatigue syndrome (CFS) is characterized by
disabling fatigue, substantial impairment in concentration
and memory, and concomitant skeletal and muscular pain.1
However, the pathogenesis and etiology of CFS remains
elusive. The incidence of CFS in Western countries is about& Formosan Medical Association. All rights reserved.
702 H.-Y. Zhang et al.0.2e0.5%, and it affects women at 2e4 times the rate of
men. Several lines of evidence have suggested that
abnormal expression of various cytokines, such as tumor
necrosis factor alfa (TNF-a), interleukin 6 (IL-6), trans-
forming growth factor beta 1(TGF-b1), and TNF receptor 1
(TNFR1), are implicated in CFS.2e4 A genetic profiling study
indicated that CFS is a disease with heterogeneous char-
acteristics, and other studies also suggest that patients
with CFS also have immunologic disturbances and viral
infections.2
The TGF-b superfamily is highly conserved throughout
the animal kingdom. It is a multifunctional cytokine that
regulates a wide variety of cellular processes, such as cell
growth, differentiation, extracellular matrix formation,
hematopiesis, angiogenesis, chemotaxis, and immune
responses.5 Three isoforms (TGF-b1, TGF-b2, and TGF-b3)
with similar structures and in vitro biologic activities
have been identified in mammalian cells.6 TGF-b1 is one of
the most potent isoform that was originally discovered for
its capacity to induce anchorage-independent growth of
normal rat kidney cells and fibroblasts, and it has become
well known as a tumor-inhibiting factor because it mediates
growth inhibition and apoptosis.7 High levels of bioactive
TGF-b have been found in the serum of patients with CFS
compared with controls.8 Since CFS is an idiopathic disorder
with the main symptom of profound fatigue, Chao et al9
developed a murine model for quantifying fatigue and
found an increased serum TGF-b concentration in mice with
fatigue induced by inoculation with Corynebacterium
parvum antigen or the relatively avirulent Me49 strain of
Toxoplasma gondii. In addition, Kennedy et al2 also found
that patients with CFS had an increased neutrophil
apoptosis and a high concentration of active TGF-b, sug-
gesting that the detectable abnormality in immune cells in
patients with CFS is closely associated with the participa-
tion of TGF-b. However, a recent study by Tomoda et al10
indicated that when peripheral blood mononuclear cells
obtained from patients with CFS were cultured with lipo-
polysaccharide or phytohemagglutinin, these patients
showed significantly lower mRNA levels and TGF-b1
production than normal controls. Thus, the functions of
TGF- b1 in CFS are still not clear.
Given the evidence that TGF-b1 might be implicated in
the pathogenesis of CFS, and that peripheral blood mono-
nuclear cells (PBMC) are an indicator of abnormal biologic
reactions, we investigated TGF-b1 mRNA expression in
PBMCs of patients with CFS using FQ-RT-PCR. The rela-
tionship between TGF-b1 and the pathogenesis of CFS is
also evaluated.
Materials and methods
Study patients
Blood samples were collected from 25 men and 38 women
volunteers (from the Beijing Friendship Hospital, aged
23e58 years, with an average of age of 41) who were diag-
nosed according to the diagnostic criteria of CFS described
by the U.S. Centers for Disease Control and Prevention.11
Symptom Checklist 90, the Hamilton depression scale, andthe Wechsler memory scale were also adopted to rule out
the psychiatric illness such as depression. Fifty healthy
volunteers were used as normal controls (21 men and 29
women, aged 23e64 years, with an average age of 38). Fifty
patients (five patients with liver cancer, five with lung
cancer, seven with diabetes mellitus, eight with systemic
lupus erythematosus, seven with rheumatoid arthritis, two
with multiple sclerosis, seven with primary Sjogren
syndrome, two with gonioma, and seven with primary biliary
cirrhosis, of which 20 were men and 30 were women, aged
21e69 years, with an average age of 42) were also included
in this study as disease controls. All patients gave written
informed content prior to participation in the study, and
they were followed-up for a period of time.
Extraction of RNA from PBMCs
PBMCs were harvested from 3 mL of blood anticoagulated
with ethylenediaminetetraacetic acid (EDTA) and sepa-
rated with Ficoll, and 1 mL of Trizol was added to PBMCs
and the solution was mixed well at room temperature for
5 min, followed by the addition of 0.2 mL of chloroform.
After shaking vigorously, the mixture was incubated at
room temperature for 5 min, followed by centrifugation at
12,000 g for 15 min at 4C. The colorless, upper aqueous
phase was carefully removed in a clean microcentrifuge
tube and same volume of isopropanol was added and mixed
to allow the ribonucleic acid (RNA) to precipitate at room
temperature for 10 min, followed by centrifugation at
12,000 g for 15 min at 4C. After the supernatant was
removed, the RNA pellet was washed with 1 mL of 75%
ethanol and vortexed and centrifuged at 7500 g for 5 min at
4C. The remaining ethanol was removed and allowed to
dry at room temperature. Extracted RNA was finally resus-
pended in 20 mL of RNase free water. Analysis for integrity
and quantity yielded A260/280 nm in all cases, with clear
ribosomal RNA bands on gel analysis.
FQ-RT-PCR
Reverse transcription kits of SYBR Prime Script RT-PCR
(TaKaRa) were used to convert RNA into cDNA according
to the manufacturer’s instructions. TGF-b1 was probed with
the following primers, 50- GCCCTGGACACCAACTATTGC-30
(forward), 50-AGGCTCCAAATGTAGGGGCAG-30 (reverse),
and with a product size of 161 bps. The internal marker
gene of b-actin was probed with the primers of 50-TGTA
CGCCAACACAGTGCTG-30 (forward), and 50-TCAGGAGGAGC
AATGATCTTG-30 (reverse), with the product size of 123 bps.
Polymerase chain reaction (PCR) was performed with an
initial denaturation at 95C for 3 min, followed by 35 cycles
of 95C (30 s), 62C (30 s), 72C (20 s), then 1 min at 78C
for elongation. All experiments were performed using
a Light Cycler (Roche). The reactions for each sample were
duplicated in two wells for both b-actin and TGF-b1, and
the mean value was calculated as the cycle thresholds (Ct).
DCtZ Ct (TGF-b1)-Ct (b-actin) was taken as the index of
assessing the expression level of TGF-b1. Water was used as
negative and quality controls, which were performed
simultaneously with experimental groups.
Figure 2 RT-PCR product of TGF-b1 (161 bp). 1Z the
product of TGF-b1 from a healthy individual; 2, 3, 4, 5, and
6Z the products of TGF-b1 from individual patients with CFS;
MZmarker.
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The data were represented as mean SD. Differences
between groups were analyzed using t-test or analysis of
variance when more than two groups were compared. The
statistical analysis was performed using SPSS software
version 11.0, and p< 0.05 was considered to be significant
for all tests.
Results
PBMCs RNA preparation
Analysis of the integrity and quantity of RNA obtained
revealed that all of the sample yielded a ratio of A260/
280 1.8, with two clear ribosomal RNA bands on gel
analysis, suggesting that the RNA obtained in our experi-
ments was intact without degradation (Fig. 1).
FQ-RT-PCR
To confirm the correctness of the PCR production, the PCR
products were run on a 2% agarose gel, stained with ethidium
bromide and imaged under ultraviolet illumination. In each
lane a product between 100e200 base pairs can be clearly
observed, which was consistent with the length (161 bp) of
the target gene (Fig. 2). The melting curves of quantitative
PCR showed two visible peaks (b-actin and TGF-b1), indi-
cating very few nonspecific products in the reaction (Fig. 3).
We used DCtZ Ct (TGF-b1)-Ct (b-actin) as the index to
assess the expression of TGF-b1, different TGF-b1 mRNA
levels in different groups was calculated. The TGF-b1 mRNA
expression in the CFS group was DDCtZ 1.17 0.58, which
was higher than that of the disease control group
(DDCtZ 0.07 1.08, dfZ 111, p< 0.01) and healthy
controls (DDCtZ 0.00 1.63, dfZ 111, p< 0.01). No
significant difference was found between the disease control
group and healthy controls in the levels of TGF-b1 mRNA
(p> 0.05). We also used 2DDCt methods to express the
relative amount of TGF- b1 compared with the beta-actin.
The results showed that the expression of TGF- b1 in the
CFS group was significantly higher compared with that of the
disease and healthy control groups; the ratios were 2.3/1
and 2.4/1 respectively (p< 0.01).
Discussion
Although the pathophysiology of CFS is not clear, CFS
patients demonstrate abnormal immune responses.12 In ourFigure 1 RNA extracted from PBMCs. Two clear ribosomal
RNA bands (28S and 18S) indicate intact RNA. 1, 2, and 3
represent the RNA from three healthy individuals in the same
test.study, we found that the TGF-b1 mRNA expression in PBMCs
in 63 cases of CFS was increased compared with that of the
disease and healthy controls. Since the target tissue of CFS
has not been clearly detected, it is possible that TGF-b1
expression is high in multiple tissues; further experiments
are needed to test this hypothesis.
TGF-b is a multifunctional cytokine involved in numerous
biologic activities, such as cell cycle control, hematopoi-
esis, angiogenesis, chemotaxis, and immune responses.5,13
TGF-b1 can inhibit the activation of macrophages, the
activity of natural killer cells, the proliferation of T or B
cells, and the maturation of cytotoxic T lymphocytes.14
Bennett et al15 found that patients with CFS had signifi-
cantly higher levels of bioactive TGF-b1 in serum compared
with the healthy subjects and disease controls, such as
systemic lupus erythematosus, and multiple sclerosis, but
there was no significant difference found between the
healthy controls and the disease group. The level of
bioactive TGF-b is increased in cerebrospinal fluid following
physical exercise, and the increased level is related to
fatigue and various physiologic changes. The level of TGF-b
in the brain is also correlated with fatigue induced by viral
infection.16
Even though the exact etiology of CFS remains unclear, it
is believed that T-cell mediated immune responses play an
important role in CFS pathogenesis.17 The neutrophils in
patients with CFS have an increased rate of apoptosis. Since
neutrophils are the major effector cells of the innate
immune system, it is likely that the increased neutrophil
apoptosis influences the innate immune system of these
patients. Accelerated apoptosis indicates that the body is
in a reactivation of viral infection or in a toxic state, which
can reprogram apoptotic pathways and therefore affect
immune functions.2 TGF-b modulates immune functions by
interfering with angtigen presentation, inhibiting T cell
differentiation and cytokine secretion, and therefore
inducing the acceleration of apoptosis in patients with
CFS.13 TGF-b1 activates apoptotic pathways, such as Smad3
and mitogen-activated protein (MAP) kinase, including P38,
c-Jun-N-terminal kinase (JNK), and extracellular signal
regulated kinase.18 The TGF-b regulated apoptosis is cell
type- and context-dependent; indeed, TGF-b provides
signals for both cell survival and apoptosis. Nevertheless,
TGF-b signaling also cooperates with the death receptor
apoptotic pathway (Fas, TNF); with the intracellular
modulators of apoptosis JNK and p38 MAP kinases.19 TGF-b1
accelerates leukocyte apoptosis by inhibiting cell adhesion
Figure 3 Melting curves of b-actin (Curve 1) and TGF-b1 (Curve 2), there were only two visible peaks. 1Z Curve 1; 2Z Curve 2.
704 H.-Y. Zhang et al.and migration. The increased apoptosis in patients with CFS
may be a consequence of the combined actions of several
factors. The phagocytosis of apoptotic cells by macro-
phages will stimulate the secretion of TGF-b.
Our results show that the TGF-b1 expression in PBMCs is
significantly elevated in patients with CFS, suggesting
TGF-b1 might be correlated to the pathogenesis of CFS.
This result may provide a scientific basis for finding
a treatment for CFS.
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